Appendix 4C - quarterly
Released
Released
Announcement PDF
W H E R E B I O T E C H N O L OG Y &
N A N O T E C H N O L O G Y M E ET
®
B I O S Y S T E M S
Imagion Biosystems
December 2018 Quarterly Update
MELBOURNE — 31 January 2019 — Imagion Biosystems Limited (ASX: IBX) (the Company), a
company dedicated to improving healthcare through the earlier detection of cancer, is pleased to
provide an update on its activities for the quarter ended 31 December 2018.
Corporate Highlights
During the quarter Imagion Biosystems entered a Master Service Agreement with the highly
regarded Australian healthtech innovation and commercialization company Planet Innovation. Under
the agreement, Planet Innovation’s world class engineering and product development team will work
with Imagion Biosystems to develop Imagion’s MagSense™ instrument technology. In December
Planet Innovation’s and Imagion Biosystems kicked off the project for the instrument system to
support the Company’s future pivotal clinical studies.
In November Imagion Biosystems raised a total of $4.3 million (before costs) through the successful
completion of the rights offering and placement of the shortfall shares under the 1-for-2 pro-rata
non-renounceable rights issue which had been announced on the basis of 1 new share for every 2
Imagion Biosystems shares held as of 7.00pm (Melbourne time) Friday 28 September 2018.
A total of 96,859,510 new shares were issued by the Company under the shortfall placement at the
Rights Issue offer price of $0.04 per share. In addition, the Company issued 34,420,000 Options
(each exercisable at $0.06, expiring 24 months after date of issue) to the Lead Manager, Pamplona
Corporate, Pty (or its nominee), as part of its placement selling fees. The funds will be used by the
Company to support R&D and basic business operations, including toxicology testing of its lead
cancer diagnostic product, as the Company makes progress toward first-in-human testing.
Corporate Outlook
In the first quarter of 2019 Imagion Biosystems expects to undertake testing of the MagSense
nanoparticle formulation for safety and toxicity. This is a significant de-risking milestone insofar as
the study will demonstrate the biological safety of the MagSense nanoparticle formulation and clear
the way for use in human studies. Regulatory and institutional review by the clinical study site will
take place following the toxicology study.
The Company is working with its contract manufacturing partner to have the nanoparticles made
under Good Manufacturing Procedures (GMP), a requirement for use in human studies, in time for
the first-in-human testing, now expected in calendar Q3.
Based on the current cash position and the slight change in schedule compared to prior guidance,
the Company has implemented a reduced expenditure plan to conserve cash while seeking additional
financing.
About Imagion Biosystems
Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging
technology. Combining biotechnology and nanotechnology the Company aims to detect cancer
and other diseases earlier and with higher specificity than is currently possible. Imagion
Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.
W H E R E B I O T E C H N O L OG Y &
N A N O T E C H N O L O G Y M E ET
®
B I O S Y S T E M S
For further information please visit www.imagionbiosystems.com
Australian Media & Investor Relations:
Matt Wright, NWR Communications
matt@nwrcommunications.com.au
+61-451-896-420
U.S. Media Contact:
Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630
Appendix 4C
Quarterly report for entities subject to Listing Rule 4.7B
+Rule 4.7B
Appendix 4C
Quarterly report for entities subject to Listing Rule 4.7B
Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16
Name of entity
Imagion Biosystems Limited
ABN
Quarter ended (“current quarter”)
42 616 305 027
31 December 2018
Consolidated statement of cash flows
Current quarter
$A’000
Year to date (12
months)
$A’000
79
159
(861)
(2,555)
(b) product manufacturing and operating
costs
-
-
(c) advertising and marketing
(5)
(81)
(d) leased assets
-
(5)
(e) staff costs
(768)
(3,320)
(f)
(253)
(986)
1.
Cash flows from operating activities
1.1
Receipts from customers
1.2
Payments for
(a) research and development
administration and corporate costs
1.3
Dividends received (see note 3)
-
-
1.4
Interest received
6
67
1.5
Interest and other costs of finance paid
(1)
(2)
1.6
Income taxes paid
-
-
1.7
Government grants and tax incentives
-
-
1.8
Other (GST Refund)
10
50
1.9
Net cash from / (used in) operating
activities
(1,793)
(6,673)
2.
Cash flows from investing activities
2.1
Payments to acquire:
(a) property, plant and equipment
-
(33)
(b) businesses (see item 10)
-
-
(c) investments
-
-
+ See chapter 19 for defined terms
1 September 2016
Page 1
Appendix 4C
Quarterly report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
Current quarter
$A’000
Year to date (12
months)
$A’000
(d) intellectual property
-
-
(e) other non-current assets
-
-
(a) property, plant and equipment
-
-
(b) businesses (see item 10)
-
-
(c) investments
-
-
(d) intellectual property
-
-
(e) other non-current assets
-
-
2.3
Cash flows from loans to other entities
-
-
2.4
Dividends received (see note 3)
-
-
2.5
Other (provide details if material)
-
-
2.6
Net cash from / (used in) investing
activities
-
(33)
3.
Cash flows from financing activities
3.1
Proceeds from issues of shares
4,286
4,286
3.2
Proceeds from issue of convertible notes
-
-
3.3
Proceeds from exercise of share options
-
-
3.4
Transaction costs related to issues of
shares, convertible notes or options
(54)
(54)
3.5
Proceeds from borrowings
-
-
3.6
Repayment of borrowings
(36)
(130)
3.7
Transaction costs related to loans and
borrowings
-
-
3.8
Dividends paid
-
-
3.9
Other (provide details if material)
-
-
3.10
Net cash from / (used in) financing
activities
4,196
4,102
4.
Net increase / (decrease) in cash and
cash equivalents for the period
4.1
Cash and cash equivalents at beginning of
quarter/year to date
1,986
6,901
4.2
Net cash from / (used in) operating
activities (item 1.9 above)
(1,793)
(6,673)
4.3
Net cash from / (used in) investing activities
(item 2.6 above)
-
(33)
4.4
Net cash from / (used in) financing activities
(item 3.10 above)
4,196
4,102
2.2
Proceeds from disposal of:
+ See chapter 19 for defined terms
1 September 2016
Page 2
Appendix 4C
Quarterly report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
Current quarter
$A’000
Year to date (12
months)
$A’000
4.5
Effect of movement in exchange rates on
cash held
(22)
70
4.6
Cash and cash equivalents at end of
quarter
4,367
4,367
5.
Reconciliation of cash and cash
equivalents
Current quarter
$A’000
Previous quarter
$A’000
at the end of the quarter (as shown in the
consolidated statement of cash flows) to the
related items in the accounts
5.1
Bank balances
4,367
1,986
5.2
Call deposits
-
-
5.3
Bank overdrafts
-
-
5.4
Other (provide details)
-
-
5.5
Cash and cash equivalents at end of
quarter (should equal item 4.6 above)
4,367
1,986
6.
Payments to directors of the entity and their associates
Current quarter
$A'000
6.1
Aggregate amount of payments to these parties included in item 1.2
108
6.2
Aggregate amount of cash flow from loans to these parties included
in item 2.3
-
6.3
Include below any explanation necessary to understand the transactions included in
items 6.1 and 6.2
7.
Payments to related entities of the entity and their
associates
7.1
Aggregate amount of payments to these parties included in item 1.2
-
7.2
Aggregate amount of cash flow from loans to these parties included
in item 2.3
-
7.3
Include below any explanation necessary to understand the transactions included in
items 7.1 and 7.2
+ See chapter 19 for defined terms
1 September 2016
Current quarter
$A'000
Page 3
Appendix 4C
Quarterly report for entities subject to Listing Rule 4.7B
8.
Financing facilities available
8.1
Total facility amount
at quarter end
$A’000
Amount drawn at
quarter end
$A’000
Loan facilities
-
-
8.2
Credit standby arrangements
-
-
8.3
Other (please specify)
-
-
8.4
Include below a description of each facility above, including the lender, interest rate and
whether it is secured or unsecured. If any additional facilities have been entered into or are
proposed to be entered into after quarter end, include details of those facilities as well.
9.
Estimated cash outflows for next quarter
$A’000
9.1
Research and development
1,256
9.2
Product manufacturing and operating costs
-
9.3
Advertising and marketing
-
9.4
Leased assets
16
9.5
Staff costs
688
9.6
Administration and corporate costs
693
9.7
Other (provide details if material)
9.8
Total estimated cash outflows
10.
Acquisitions and disposals of
business entities
(items 2.1(b) and 2.2(b) above)
10.1
Add notes as necessary for an
understanding of the position
2,652
Acquisitions
Disposals
Name of entity
-
-
10.2
Place of incorporation or
registration
-
-
10.3
Consideration for acquisition or
disposal
-
-
10.4
Total net assets
-
-
10.5
Nature of business
-
-
+ See chapter 19 for defined terms
1 September 2016
Page 4
Appendix 4C
Quarterly report for entities subject to Listing Rule 4.7B
Compliance statement
1
This statement has been prepared in accordance with accounting standards and policies which
comply with Listing Rule 19.11A.
2
This statement gives a true and fair view of the matters disclosed.
Sign here:
............................................................
Director
Print name:
Robert Proulx
Date: 31 January 2019
Notes
1.
The quarterly report provides a basis for informing the market how the entity’s activities have been
financed for the past quarter and the effect on its cash position. An entity that wishes to disclose
additional information is encouraged to do so, in a note or notes included in or attached to this
report.
2.
If this quarterly report has been prepared in accordance with Australian Accounting Standards,
the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If
this quarterly report has been prepared in accordance with other accounting standards agreed by
ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this
report.
3.
Dividends received may be classified either as cash flows from operating activities or cash flows
from investing activities, depending on the accounting policy of the entity.
+ See chapter 19 for defined terms
1 September 2016
Page 5
Share your feedback
Discover